Alaunos Therapeutics, a TCR-T biotech formerly known as Ziopharm Oncology, will shutter its lead program, lay off 60% of staff and seek a sale or other form of transaction. Announced after Monday’s closing bell, the move comes as the biotech’s runway dwindles…